Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success

by Cazzaniga, Marina Elena, Danesi, Romano, Girmenia, Corrado, Invernizzi, Pietro, Elvevi, Alessandra, Uguccioni, Massimo
Published in Breast Cancer Res Treat (2019)

Metronomic Chemotherapy

by Cazzaniga, Marina Elena, Cordani, Nicoletta, Capici, Serena, Cogliati, Viola, Riva, Francesca, Cerrito, Maria Grazia
Published in Cancers (Basel) (2021)

Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study

by O’Shaughnessy, Joyce, Brezden-Masley, Christine, Cazzaniga, Marina, Dalvi, Tapashi, Walker, Graham, Bennett, James, Ohsumi, Shozo
Published in Breast Cancer Res (2020)

Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects

by Pilla, Lorenzo, Alberti, Andrea, Di Mauro, Pierluigi, Gemelli, Maria, Cogliati, Viola, Cazzaniga, Marina Elena, Bidoli, Paolo, Maccalli, Cristina
Published in Cancers (Basel) (2020)

The Role for Tocilizumab in COVID-19 Patients: Reflections on Monza Cohort Data

by Capici, Serena, Sala, Luca, Galimberti, Stefania, Valsecchi, Maria Grazia, Squillace, Nicola, Gustinetti, Giulia, Cazzaniga, Marina Elena, Bonfanti, Paolo
Published in Infect Drug Resist (2021)

Methotrexate inhibits SARS‐CoV‐2 virus replication “in vitro”

by Caruso, Arnaldo, Caccuri, Francesca, Bugatti, Antonella, Zani, Alberto, Vanoni, Marco, Bonfanti, Paolo, Cazzaniga, Marina E., Perno, Carlo F., Messa, Cristina, Alberghina, Lilia
Published in J Med Virol (2020)

Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study

by Zeppellini, Annalisa, Galimberti, Stefania, Leone, Biagio Eugenio, Pacifico, Claudia, Riva, Francesca, Cicchiello, Federica, Capici, Serena, Maggioni, Claudia, Sala, Luca, Cazzaniga, Marina Elena
Published in BMC Cancer (2021)

Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study

by Cerrito, Maria Grazia, De Giorgi, Marco, Pelizzoni, Davide, Bonomo, Sara Maria, Digiacomo, Nunzio, Scagliotti, Arianna, Bugarin, Cristina, Gaipa, Giuseppe, Grassilli, Emanuela, Lavitrano, Marialuisa, Giovannoni, Roberto, Bidoli, Paolo, Cazzaniga, Marina Elena
Published in Oncotarget (2018)

Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?

by Cazzaniga, Marina Elena, Biganzoli, Laura, Cortesi, Laura, De Placido, Sabino, Donadio, Michela, Fabi, Alessandra, Ferro, Antonella, Generali, Daniele, Lorusso, Vito, Milani, Andrea, Montagna, Emilia, Munzone, Elisabetta, Orlando, Laura, Pizzuti, Laura, Simoncini, Edda, Zamagni, Claudio, Pappagallo, Giovanni L
Published in Onco Targets Ther (2019)

Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II...

by Caputo, Roberta, Cazzaniga, Marina Elena, Sbrana, Andrea, Torrisi, Rosalba, Paris, Ida, Giordano, Monica, Montesarchio, Vincenzo, Guarneri, Valentina, Amaducci, Laura, Bilancia, Domenico, Cilenti, Giuseppina, Fabi, Alessandra, Collovà, Elena, Schirone, Alessio, Bonizzoni, Erminio, Celio, Luigi, De Placido, Sabino, De Laurentiis, Michelino
Published in BMC Cancer (2020)

Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (It...

by Leo, Silvana, Arnoldi, Ermenegildo, Repetto, Lazzaro, Coccorullo, Zaira, Cinieri, Saverio, Fedele, Palma, Cazzaniga, Marina, Lorusso, Vito, Latorre, Agnese, Campanella, Giovanna, Ciccarese, Mariangela, Accettura, Caterina, Pisconti, Salvatore, Rinaldi, Antonio, Brunetti, Cosimo, Raffaele, Mimma, Coltelli, Luigi, Spazzapan, Salvatore, Fratino, Lucia, Petrucelli, Luciana, Biganzoli, Laura
Published in Oncologist (2018)

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study

by Di Cosimo, Serena, La Verde, Nicla, Moretti, Anna, Cazzaniga, Marina Elena, Generali, Daniele, Bianchi, Giulia Valeria, Mariani, Luigi, Torri, Valter, Crippa, Flavio, Paolini, Biagio, Scaperrotta, Gianfranco, De Santis, Maria Carmen, Di Nicola, Massimo, Apolone, Giovanni, Gulino, Alessandro, Tripodo, Claudio, Colombo, Mario Paolo, Folli, Secondo, de Braud, Filippo
Published in PLoS One (2019)

Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting

by Generali, Daniele, Montemurro, Filippo, Bordonaro, Roberto, Mafodda, Antonino, Romito, Sante, Michelotti, Andrea, Piovano, Pierluigi, Ionta, Maria Teresa, Bighin, Claudia, Sartori, Donata, Frassoldati, Antonio, Cazzaniga, Marina Elena, Riccardi, Ferdinando, Testore, Franco, Vici, Patrizia, Barone, Carlo Antonio, Schirone, Alessio, Piacentini, Federico, Nolè, Franco, Molino, Annamaria, Latini, Luciano, Simoncini, Edda Lucia, Roila, Fausto, Cognetti, Francesco, Nuzzo, Francesco, Foglietta, Jennifer, Minisini, Alessandro Marco, Goffredo, Francesca, Portera, Giuseppe, Ascione, Gilda, Mariani, Gabriella
Published in Oncologist (2017)

NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2(+) breast cancer

by Jacobs, Samuel A., Robidoux, André, Abraham, Jame, Pérez-Garcia, José Manuel, La Verde, Nicla, Orcutt, James M., Cazzaniga, Marina E., Piette, Fanny, Antolín, Silvia, Aguirre, Elena, Cortes, Javier, Llombart-Cussac, Antonio, Di Cosimo, Serena, Kim, Rim S., Feng, Huichen, Lipchik, Corey, Lucas, Peter C., Srinivasan, Ashok, Wang, Ying, Song, Nan, Gavin, Patrick G., Balousek, April D., Paik, Soonmyung, Allegra, Carmen J., Wolmark, Norman, Pogue-Geile, Katherine L.
Published in Breast Cancer Res (2019)

Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ br...

by Jacobs, Samuel A., Robidoux, André, Abraham, Jame, Pérez-Garcia, José Manuel, La Verde, Nicla, Orcutt, James M., Cazzaniga, Marina E., Piette, Fanny, Antolín, Silvia, Aguirre, Elena, Cortes, Javier, Llombart-Cussac, Antonio, Di Cosimo, Serena, Kim, Rim S., Feng, Huichen, Lipchik, Corey, Lucas, Peter C., Srinivasan, Ashok, Wang, Ying, Song, Nan, Gavin, Patrick G., Balousek, April D., Paik, Soonmyung, Allegra, Carmen J., Wolmark, Norman, Pogue-Geile, Katherine L.
Published in Breast Cancer Res (2020)

Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study

by Cazzaniga, Marina, Verusio, Claudio, Ciccarese, Mariangela, Fumagalli, Alberto, Sartori, Donata, Valerio, Maria Rosaria, Airoldi, Mario, Moretti, Gabriella, Ficorella, Corrado, Arcangeli, Valentina, Diodati, Lucrezia, Zambelli, Alberto, Febbraro, Antonio, Generali, Daniele, Pistelli, Mirco, Garrone, Ornella, Musolino, Antonino, Vici, Patrizia, Maur, Michela, Mentuccia, Lucia, La Verde, Nicla, Bianchi, Giulia, Artale, Salvatore, Blasi, Livio, Piezzo, Michela, Atzori, Francesco, Turletti, Anna, Benedetto, Chiara, Cursano, Maria Concetta, Fabi, Alessandra, Gebbia, Vittorio, Schirone, Alessio, Palumbo, Raffaella, Ferzi, Antonella, Frassoldati, Antonio, Scavelli, Claudio, Clivio, Luca, Torri, Valter
Published in Oncotarget (2018)

Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study

by Cazzaniga, Marina, Verusio, Claudio, Ciccarese, Mariangela, Fumagalli, Alberto, Sartori, Donata, Ancona, Cristina, Airoldi, Mario, Moretti, Gabriella, Ficorella, Corrado, Arcangeli, Valentina, Diodati, Lucrezia, Zambelli, Alberto, Febbraro, Antonio, Generali, Daniele, Pistelli, Mirco, Garrone, Ornella, Musolino, Antonino, Vici, Patrizia, Maur, Michela, Mentuccia, Lucia, La Verde, Nicla, Bianchi, Giulia, Artale, Salvatore, Blasi, Livio, Piezzo, Matilde, Atzori, Francesco, Turletti, Anna, Benedetto, Chiara, Cursano, Maria Concetta, Fabi, Alessandra, Gebbia, Vittorio, Schirone, Antonio, Palumbo, Raffaella, Ferzi, Antonella, Frassoldati, Antonio, Scavelli, Claudio, Clivio, Luca, Torri on behalf of The EVA Study Group, Valter
Published in Oncotarget (2018)

Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study

by Cazzaniga, Marina, Verusio, Claudio, Ciccarese, Mariangela, Fumagalli, Alberto, Sartori, Donata, Valerio, Maria Rosaria, Airoldi, Mario, Moretti, Gabriella, Ficorella, Corrado, Arcangeli, Valentina, Diodati, Lucrezia, Zambelli, Alberto, Febbraro, Antonio, Generali, Daniele, Pistelli, Mirco, Garrone, Ornella, Musolino, Antonino, Vici, Patrizia, Maur, Michela, Mentuccia, Lucia, La Verde, Nicla, Bianchi, Giulia, Artale, Salvatore, Blasi, Livio, Piezzo, Matilde, Atzori, Francesco, Turletti, Anna, Benedetto, Chiara, Cursano, Maria Concetta, Fabi, Alessandra, Gebbia, Vittorio, Schirone, Alessio, Palumbo, Raffaella, Ferzi, Antonella, Frassoldati, Antonio, Scavelli, Claudio, Clivio, Luca, Torri on behalf of The EVA Study Group, Valter
Published in Oncotarget (2018)

Is There Still a Role for Endocrine Therapy Alone in HR+/HER2– Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulves...

by Cazzaniga, Marina Elena, Verusio, Claudio, Ciccarese, Mariangela, Fumagalli, Alberto, Sartori, Donata, Valerio, Maria Rosaria, Airoldi, Mario, Moretti, Gabriella, Ficorella, Corrado, Gianni, Lorenzo, Michelotti, Andrea, Zambelli, Alberto, Febbraro, Antonio, Generali, Daniele, Pistelli, Mirco, Garrone, Ornella, Musolino, Antonino, Vici, Patrizia, Maur, Michela, Mentuccia, Lucia, La Verde, Nicla, Bianchi, Giulia Valeria, Artale, Salvatore, Blasi, Livio, De Laurentiis, Michelino, Atzori, Francesco, Turletti, Anna, Porpiglia, Mauro, Santini, Daniele, Fabi, Alessandra, Gebbia, Vittorio, Schirone, Alessio, Palumbo, Raffaella, Ferzi, Antonella, Frassoldati, Antonio, Scavelli, Claudio, Clivio, Luca, Giordano, Monica, Donadio, Michela, Biganzoli, Laura, Del Mastro, Lucia, Bisagni, Giancarlo, Livi, Lorenzo, Natoli, Clara, Montemurro, Filippo, Riccardi, Ferdinando, Romagnoli, Emanuela, Marchetti, Paolo, Torri, Valter, Pronzato, Paolo, Mustacchi, Giorgio
Published in Breast Care (Basel) (2020)

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

by Bon, Giulia, Pizzuti, Laura, Laquintana, Valentina, Loria, Rossella, Porru, Manuela, Marchiò, Caterina, Krasniqi, Eriseld, Barba, Maddalena, Maugeri-Saccà, Marcello, Gamucci, Teresa, Berardi, Rossana, Livi, Lorenzo, Ficorella, Corrado, Natoli, Clara, Cortesi, Enrico, Generali, Daniele, La Verde, Nicla, Cassano, Alessandra, Bria, Emilio, Moscetti, Luca, Michelotti, Andrea, Adamo, Vincenzo, Zamagni, Claudio, Tonini, Giuseppe, Barchiesi, Giacomo, Mazzotta, Marco, Marinelli, Daniele, Tomao, Silverio, Marchetti, Paolo, Valerio, Maria Rosaria, Mirabelli, Rosanna, Russo, Antonio, Fabbri, Maria Agnese, D’Ostilio, Nicola, Veltri, Enzo, Corsi, Domenico, Garrone, Ornella, Paris, Ida, Sarobba, Giuseppina, Giotta, Francesco, Garufi, Carlo, Cazzaniga, Marina, Del Medico, Pietro, Roselli, Mario, Sanguineti, Giuseppe, Sperduti, Isabella, Sapino, Anna, De Maria, Ruggero, Leonetti, Carlo, Di Leo, Angelo, Ciliberto, Gennaro, Falcioni, Rita, Vici, Patrizia
Published in J Exp Clin Cancer Res (2020)